Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) Shares Shorted: Short Interest Down 78.4% in October

Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) was the target of a large drop in short interest in October. As of October 15th, there was short interest totaling 3,004 shares, a drop of 78.4% from the September 30th total of 13,919 shares. Currently, 0.0% of the shares of the stock are short sold. Based on an average trading volume of 19,959 shares, the short-interest ratio is currently 0.2 days.

Emmaus Life Sciences Price Performance

Shares of OTCMKTS:EMMA opened at $0.05 on Tuesday. The company’s 50 day simple moving average is $0.05 and its 200 day simple moving average is $0.02. The stock has a market capitalization of $3.23 million, a price-to-earnings ratio of -0.51 and a beta of 9.73. Emmaus Life Sciences has a 1 year low of $0.01 and a 1 year high of $0.09.

Emmaus Life Sciences (OTCMKTS:EMMA) last released its earnings results on Friday, August 14th. The company reported $0.02 earnings per share for the quarter. The business had revenue of $6.32 million for the quarter.

Emmaus Life Sciences Company Profile

Emmaus Life Sciences, Inc is a biopharmaceutical company focused primarily on developing and commercializing treatments for rare and serious diseases. The company’s best-known product is Endari (L-glutamine), an oral powder approved by the U.S. Food and Drug Administration to reduce the acute complications of sickle cell disease in adults and children aged five and older.

Historically, Emmaus has concentrated on therapies for sickle cell disease and other conditions with significant unmet medical needs.